Version May 2024
| Class I - There is evidence and/or general agreement that the following approach is effective for the maintenance of sinus rhythm in patients with AF |
| • Treatment of precipitating or reversible causes of AF before initiating therapy with antiarrhythmic drugs. |
| Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approaches for the maintenance of sinus rhythm in patients with AF |
| • Antiarrhythmic drug therapy to maintain sinus rhythm and prevent tachycardia-induced cardiomyopathy. |
| • Infrequent, well tolerated recurrent episodes of recurrent AF is reasonable as a successful outcome of antiarrhythmic drug therapy. |
| • Outpatient initiation of therapy in patients with no associated heart disease when the antiarrhythmic drug is well tolerated. |
| • In patients with lone AF and no structural heart disease, outpatient initiation of propafenone or flecainide therapy in patients with paroxysmal AF who are in sinus rhythm at the time of drug initiation. |
| • Sotalol in outpatients in sinus rhythm who have little or no heart disease, are prone to paroxysmal AF, a baseline uncorrected QT interval less than 460 msec, normal serum electrolytes, and no risk factors for class III drug-related proarrhythmia. |
| • Catheter ablation as an alternative to antiarrhythmic drug therapy to prevent recurrent AF in symptomatic patients with little or no left atrial enlargement. |
| Class III - There is evidence and/or general agreement that the following approaches are not useful or may be harmful for the maintenance of sinus rhythm in patients with AF |
| • Use of a particular antiarrhythmic drug is not recommended in patients with well-defined risk factors for proarrhythmia with that drug. |
| • Antiarrhythmic drug therapy is not recommended in patients with advanced sinus node disease or atrioventricular node dysfunction unless they have a functioning electronic cardiac pacemaker. |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
